Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03001843 · ClinicalTrials.gov registry record · Phase 4

Ketamine vs Hydromorphone

A Phase 4 study, sponsored by University of Florida.

Completed
Registry status
Phase 4
Development phase
54
Enrollment target

NCT03001843: Completed Phase 4 study, sponsored by University of Florida.

NCT03001843 is a Phase 4 study that has completed, run by University of Florida. The registered enrollment target is 54 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03001843, a Phase 4 study, has completed, sponsored by University of Florida.

COMPLETED
Registry status
Phase 4
Development phase
54 participants
Enrollment target

Study Summary

This study will help to determine if investigators can minimize narcotic use in laparoscopic gastric bypass patients while maintaining adequate pain control. This will allow investigators to minimize the negative side effects of narcotics which is a goal in this population.

Primary Outcome

Used to translate the dose and route of each of the opioids the patient has received over the last 48 hours to a parenteral morphine equivalent using a standard conversion table. SD standard deviation, mg: milligrams, pain measured on a 0-10 scale

Interventions

  • DRUG Ketamine
  • DRUG Narcotics
  • BEHAVIORAL pain scale

Trial Details

FieldValue
Enrollment Target 54 participants
Start Date 2017-02-22
Est. Completion 2018-12-21
Phase Phase 4
University of Florida

1,106 total trials

What the finished NCT03001843 record still lists

NCT03001843 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (90% lower).

The record links to 0 conditions, and to 3 interventions - of which Ketamine is the first listed.

NCT03001843 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03001843 about?

NCT03001843 is a clinical study titled "Ketamine vs Hydromorphone". This study will help to determine if investigators can minimize narcotic use in laparoscopic gastric bypass patients while maintaining adequate pain control. This will allow investigators to minimize the negative side effects of narcotics which is a goal in this population.

What is the current status of trial NCT03001843?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 54 participants. The study started on 2017-02-22. Estimated completion is 2018-12-21.

What interventions are being tested in trial NCT03001843?

The interventions under investigation include: Ketamine (DRUG), Narcotics (DRUG), pain scale (BEHAVIORAL).

Who is sponsoring clinical trial NCT03001843?

This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03001843's enrollment target sits among peer trials

54 1223rd of 2000 higher than 772 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01269853 · 54 participants · Phase 1

    Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA

  • NCT02390752 · 54 participants · Phase 1

    Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...

  • NCT02991248 · 54 participants · NA

    Improve Dynamic Lateral Balance of Humans With SCI

  • NCT02993900 · 54 participants · NA

    Image-Guided Gynecologic Brachytherapy

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03001843, the US trial registry maintained by the National Library of Medicine. NCT03001843 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.